Market Overview

Corporate Reputation of Pharma, 2017-2018 - The Patient Perspective of 169 US Patients -


The "The
Corporate Reputation of Pharma, 2017 - The Patient Perspective - US
report has been added to's

US patient groups are traditionally more sceptical and suspicious of
pharma than their peers in most of the rest of the world - which makes
the 2017 US Corporate Reputation results all the more surprising.

At first glance, not much seems to have changed in 2017. Only 32% of
2017's 169 respondent US-based patient groups thought that the pharma
industry as a whole had an "Excellent" or "Good" corporate reputation
(compared with 43% of the 1,330 respondent patient groups worldwide).
Moreover, US patient groups in 2017 ranked pharma just 5th out of nine
healthcare-industry sectors (compared with its ranking of 3rd out of
nine among patient groups worldwide).

But a closer analysis of the pharma industry's performance at specific
activities reveals a startling turnaround in attitudes in 2017 among
some US patient groups [as the charts below show].

A larger proportion of US patient groups than patient groups worldwide
in 2017 described the pharma industry as a whole as "Excellent" or
"Good" at patient centricity, at integrity, at patient-group
partnerships, at the provision of services 'beyond the pill', and at
engaging patients/patient groups in R&D.

In fact, the only activity at which US patient groups in 2017 considered
pharma to be worse than the global average was innovation (and then only
by a small margin - 43% in the US v. 48% worldwide).

Key Topics Covered:

  1. Executive Summary
  2. Patient-Group Relationships With Pharma, 2017
  3. Industry-Wide Findings, 2017
  4. Rankings Of The 30 Pharma Companies, 2017 V. 2016 Among US Patient
    Groups Familiar With The Companies
  5. Positionings Of 28 Pharma Companies, 2017 V. 2016 Among US Patient
    Groups That Work/Partner With The Companies
  6. Profiles Of The 30 Companies, 2017


I. US Patient Groups: Views On Pharma; And Recommendations For

Ii. Profiles Of Respondent US Patient Groups, 2017

Companies Mentioned

  • Abbvie
  • Acorda Therapeutics
  • Allergan
  • Amgen
  • Astellas Pharma
  • Astrazeneca
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • GSK
  • Janssen
  • Lundbeck
  • Merck & Co
  • Merck Kgaa
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Roche
  • Sanofi
  • Shire
  • Takeda
  • Teva
  • UCB
  • Vertex Pharmaceuticals

For more information about this report visit

View Comments and Join the Discussion!